Patent · US Active

17-beta-hydroxywithanolides and use thereof in treating cancer

US12018045B2 · kind B2 · utility

0Cited by

6References

10Claims

0Family size

Assignees

The United States of America, as represented by the Secretary, Department of Health and Human Services · US
Arizona Board of Regents on Behalf of the University of Arizona · US

Inventors

Thomas Joseph Sayers · Boonsboro, US
Poonam Tewary · Frederick, US
Leslie Gunatilaka · Tucson, US
Alan David Brooks · Frederick, US
Kithsiri Wijeratne · Tucson, US
Yaming Xu · Tucson, US

Key dates

Filing date	Mar 6, 2019
Grant date	Jun 25, 2024
Priority date	—
Expiry date	Mar 22, 2040

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K45/06
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are compounds suitable for enhancing cancer treatment, for example, a compound of formula (I): (I) wherein R1 is as defined herein. Also disclosed is a method of enhancing the response of cancer cells in a mammal to treatment with an apoptosis inducing ligand, a method of inducing apoptosis in cancer cells in a mammal, and a method of treating prostate cancer in mammal in need thereof comprising administration of a compound described herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.